Merck Unveils Topical Parasite Meds For Pets

Merck Animal Health has released two topical flea treatment and prevention products.

Merck Animal Health launched a pair of veterinary-exclusive, topical, ectoparasite treatment and prevention products for pets called Activyl and Activyl Tick Plus, the company reported today.

Activyl treats and prevents flea infestations in dogs and cats, while Activyl Tick Plus controls both fleas and ticks, but is available exclusively for dogs, Merck reported.

Both products contain the active ingredient indoxacarb, which kills fleas through a process called bioactivation. Indoxacarb is absorbed by a flea via contact or ingestion and is converted by certain flea enzymes into an insecticidal metabolite, which paralyzes and kills the flea. Indoxacarb also disrupts a flea’s life cycle by inhibiting the development of flea larvae in the pet’s surroundings, Merck reported.

Activyl’s only active ingredient is indoxacarb, making it safe for both cats and dogs, according to the company. Activyl Plus is available exclusively for dogs because it contains both indoxacarb and permethrin, which kills and controls ticks, but is not safe for cats and should not be used on dogs younger than eight weeks or less than four pounds.

Both products require monthly applications and are dispensed in single-application pipettes.

<HOME>

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

___

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.